Search Results for "fluid"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for fluid. Results 41 to 48 of 48 total matches.
Treatment of Clostridioides difficile Infection
The Medical Letter on Drugs and Therapeutics • Sep 06, 2021 (Issue 1632)
may have hypotension,
shock, ileus, and/or megacolon) should receive fluid
resuscitation and high-dose vancomycin ...
Clostridioides (formerly Clostridium) difficile infection
(CDI) is the most common infectious cause of
healthcare-associated diarrhea in adults. Guidelines
on management of CDI have recently been updated.
Drugs for Overactive Bladder
The Medical Letter on Drugs and Therapeutics • Mar 20, 2023 (Issue 1672)
, pelvic floor muscle
exercises, constipation management, modification of
fluid intake, and avoidance ...
In overactive bladder, involuntary bladder contractions
due to detrusor overactivity result in urinary
urgency, frequency, nocturia, and incontinence.
The prevalence of the disorder increases with age.
Nonpharmacologic treatment, including bladder
training, urge suppression, pelvic floor muscle
exercises, constipation management, modification of
fluid intake, and avoidance of dietary irritants such as
alcohol and caffeine, should be tried first.
Med Lett Drugs Ther. 2023 Mar 20;65(1672):41-5 doi:10.58347/tml.2023.1672a | Show Introduction Hide Introduction
Addendum: Aducanumab (Aduhelm) for Alzheimer's Disease
The Medical Letter on Drugs and Therapeutics • Jul 26, 2021 (Issue 1629)
; detectable
levels have been reported in human plasma, urine,
breast milk, amniotic fluid, and fetal ...
In June 2021, the FDA approved the IV amyloid beta-directed
monoclonal antibody aducanumab (Aduhelm) for treatment
of Alzheimer’s disease. The approval did not restrict use of
the drug to patients with mild cognitive impairment or mild
dementia, which was the population enrolled in the clinical
trials. Now, Biogen, with the permission of the FDA, has made
an addition to the labeling of the drug that says: Treatment with
Aduhelm should be initiated in patients with mild cognitive
impairment or mild dementia stage of disease, the population
in which treatment was initiated in clinical...
Antiviral Drugs for Seasonal Influenza for 2024-2025
The Medical Letter on Drugs and Therapeutics • Dec 09, 2024 (Issue 1717)
, swallowing, or clearing fluids from airways).
Oseltamivir is preferred for treatment of influenza ...
Influenza is generally a self-limited illness, but
pneumonia, respiratory failure, and death can occur,
especially in persons at increased risk for influenza
complications (see Table 1). Updated information on
influenza activity and antiviral resistance is available
from the CDC at cdc.gov/flu.
Med Lett Drugs Ther. 2024 Dec 9;66(1717):193-8 doi:10.58347/tml.2024.1717a | Show Introduction Hide Introduction
Influenza Vaccines for 2025-2026
The Medical Letter on Drugs and Therapeutics • Sep 29, 2025 (Issue 1738)
with active communication between the cerebrospinal
fluid (CSF) and oropharynx, nasopharynx, nose, or ear ...
Annual vaccination against influenza A and B viruses
is recommended in the US for everyone ≥6 months
old without a contraindication. Influenza vaccines
available in the US for the 2025-2026 season are listed
in Table 2.
Med Lett Drugs Ther. 2025 Sep 29;67(1738):153-8 doi:10.58347/tml.2025.1738a | Show Introduction Hide Introduction
Sunscreens
The Medical Letter on Drugs and Therapeutics • Jun 23, 2025 (Issue 1731)
systemically; detectable levels have been reported
in human plasma, urine, breast milk, amniotic fluid ...
Excessive exposure to ultraviolet (UV) radiation can
cause erythema, photoaging, and skin cancer.
Sunscreens are widely used to reduce these risks, but
questions remain about their effectiveness and safety.
In 2021, the FDA proposed a rule that would require
additional safety studies for some sunscreen active
ingredients and mandate better UVA protection in
sunscreen products.
Med Lett Drugs Ther. 2025 Jun 23;67(1731):97-102 doi:10.58347/tml.2025.1731a | Show Introduction Hide Introduction
Drugs for Migraine
The Medical Letter on Drugs and Therapeutics • Jun 12, 2023 (Issue 1678)
-17 years old.
5. Should be taken with fluids.
6. Also approved for use in patients 6-17 years old ...
An oral nonopioid analgesic is often sufficient for
acute treatment of mild to moderate migraine pain
without severe nausea or vomiting. A triptan is the
drug of choice for treatment of moderate to severe
migraine in most patients without vascular disease.
Treatment of pain when it is still mild to moderate in
intensity improves headache response and reduces
the risk of recurrence.
Med Lett Drugs Ther. 2023 Jun 12;65(1678):89-96 doi:10.58347/tml.2023.1678a | Show Introduction Hide Introduction
Adult Immunization
The Medical Letter on Drugs and Therapeutics • Oct 17, 2022 (Issue 1661)
for exposure to blood or blood contaminated
body fluids, persons on maintenance dialysis, persons ...
The Advisory Committee on Immunization Practices
(ACIP) recommends use of certain vaccines in adults
residing in the US. Routine childhood immunization
has reduced the overall incidence of some of
these vaccine-preventable diseases, but many
adults remain susceptible. Recommendations for
vaccination against COVID-19, seasonal influenza,
and monkeypox and vaccination of travelers have
been reviewed separately.